These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Protective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain. Bishnoi M; Chopra K; Kulkarni SK Pharmacol Biochem Behav; 2008 Feb; 88(4):511-22. PubMed ID: 18022680 [TBL] [Abstract][Full Text] [Related]
26. Paraventricular nucleus-pineal interaction: relevance to tardive dyskinesia. Sandyk R; Kay SR Int J Neurosci; 1992 Feb; 62(3-4):269-72. PubMed ID: 1363950 [No Abstract] [Full Text] [Related]
27. [Respiratory disorders caused by tardive dyskinesia in psychogeriatric patients]. Wils V Tijdschr Gerontol Geriatr; 1992 Jun; 23(3):109-13. PubMed ID: 1609447 [TBL] [Abstract][Full Text] [Related]
28. Yi-gan san for the treatment of neuroleptic-induced tardive dyskinesia: an open-label study. Miyaoka T; Furuya M; Yasuda H; Hayashida M; Nishida A; Inagaki T; Horiguchi J Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):761-4. PubMed ID: 18201810 [TBL] [Abstract][Full Text] [Related]
30. The effect of chronic administration of sarizotan, 5-HT1A agonist/D3/D4 ligand, on haloperidol-induced repetitive jaw movements in rat model of tardive dyskinesia. Rosengarten H; Bartoszyk GD; Quartermain D; Lin Y Prog Neuropsychopharmacol Biol Psychiatry; 2006 Mar; 30(2):273-9. PubMed ID: 16229932 [TBL] [Abstract][Full Text] [Related]
31. Organic brain dysfunction and cognitive deficits in young schizophrenic patients with tardive dyskinesia. Pourcher E; Cohen H; Cohen D; Baruch P; Bouchard RH Brain Cogn; 1993 Sep; 23(1):81-7. PubMed ID: 8105825 [TBL] [Abstract][Full Text] [Related]
32. The neuropharmacology of tardive dyskinesia, spontaneous dyskinesia, and other dystonias. Stahl SM; Davis KL; Berger PA J Clin Psychopharmacol; 1982 Oct; 2(5):321-8. PubMed ID: 6127351 [TBL] [Abstract][Full Text] [Related]
33. A biopsychosocial approach to improving quality of life in tardive dystonia. Buscombe C; Alusi SH; Kahn DA J Psychiatr Pract; 2010 Sep; 16(5):350-7. PubMed ID: 20859113 [TBL] [Abstract][Full Text] [Related]
34. Tardive and withdrawal dyskinesia in autistic children: a prospective study. Campbell M; Adams P; Perry R; Spencer EK; Overall JE Psychopharmacol Bull; 1988; 24(2):251-5. PubMed ID: 3212157 [No Abstract] [Full Text] [Related]
35. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Chouinard G; Jones B; Remington G; Bloom D; Addington D; MacEwan GW; Labelle A; Beauclair L; Arnott W J Clin Psychopharmacol; 1993 Feb; 13(1):25-40. PubMed ID: 7683702 [TBL] [Abstract][Full Text] [Related]
36. Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia. Casey DE Psychiatr Clin North Am; 1993 Sep; 16(3):589-610. PubMed ID: 8105453 [TBL] [Abstract][Full Text] [Related]
37. Propranolol-induced tardive dyskinesia in a patient with akathisia. Sandyk R Ann Neurol; 1985 Sep; 18(3):370. PubMed ID: 4051467 [No Abstract] [Full Text] [Related]